e-learning
resources
Berlin 2001
Monday 24.09.2001
Lung cancer: surveys and prognosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance
D. Dworakowska, E. Jassem, K. Wiedorn, R. Dziadziuszko, G. Kobierska, J. Skokowski, A. Bosse, J. Jassem (Gdansk, Poland; Stittgart, Germany)
Source:
Annual Congress 2001 - Lung cancer: surveys and prognosis
Session:
Lung cancer: surveys and prognosis
Session type:
Thematic Poster Session
Number:
1591
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Dworakowska, E. Jassem, K. Wiedorn, R. Dziadziuszko, G. Kobierska, J. Skokowski, A. Bosse, J. Jassem (Gdansk, Poland; Stittgart, Germany). p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance. Eur Respir J 2001; 16: Suppl. 31, 1591
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 363s
Year: 2003
The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer
Source: Eur Respir J 2001; 17: 660-666
Year: 2001
Prognostic value of p21 protein expression in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 230s
Year: 2001
HER-2/neu oncoprotein expression in nonsmall cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002
Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival
Source: Annual Congress 2010 - Biomarkers for lung cancer
Year: 2010
p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer
Source: Annual Congress 2007 - Novel genetic markers in pathology
Year: 2007
Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Survivin expression in non-small cell lung cancer
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications
Source: Eur Respir J 2009; 33: 127-133
Year: 2009
BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer
Source: Eur Respir J 2002; 19: 134-140
Year: 2002
MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 596s
Year: 2002
Distribution of BCL-2 gene expression and its prognostic value in non-small cell pulmonary cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 72s
Year: 2002
Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer
Source: International Congress 2017 – Gene signatures in bronchial diseases
Year: 2017
Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker
Source: Eur Respir J 2002; 20: Suppl. 38, 230s
Year: 2002
Prognostic value of altered cyclin D1 expression in non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 673s
Year: 2004
Fascin-1 overexpression predicts a poor prognosis in non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Apelin expression is a prognostic factor in non-small cell lung cancer
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010
Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer
Source: Eur Respir J 2013; 41: 1172-1178
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept